Physician profile
David Moise
NPI 1245734367
$2,492.34
in general payments reported to CMS, 2019-2025
25 companies · $763 in 2025
The $763 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.66 · 2022: $165 · 2023: $724 · 2024: $826 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,312.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $460.45 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $358.20 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $194.55 | 2022-2025 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $183.07 | 2022-2025 | |
| Viiv Healthcare Company | $148.79 | 2024-2025 | Apretude |
| Astrazeneca Pharmaceuticals LP | $137.55 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.77 | 2023-2025 | Jardiance, Synjardy, Ofev |
| Pfizer INC. | $106.88 | 2022-2024 | |
| Exact Sciences Corporation | $99.87 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $98.16 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $90.76 | 2024-2025 | |
| Dynavax Technologies Corporation | $59.90 | 2023-2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $57.33 | 2023 | |
| Currax Pharmaceuticals LLC | $57.15 | 2023-2024 | Contrave |
| Amgen INC. | $49.72 | 2024-2025 | Repatha, Otezla, Repatha |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $42.94 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $34.17 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $30.91 | 2023-2024 | Livalo, Zoryve |
| Actelion Pharmaceuticals US, INC. | $29.38 | 2025 | Uptravi, Opsumit |
| Astellas Pharma US INC | $28.29 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $20.93 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $20.39 | 2023 | Quviviq |
| Abbott Laboratories | $20.19 | 2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $14.55 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $14.44 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Moise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.